What are appropriate alternative statins or non‑statin lipid‑lowering agents for a patient who cannot use rosuvastatin?

Atorvastatin is the best alternative statin to rosuvastatin

For patients requiring a substitute for rosuvastatin, atorvastatin is the preferred alternative statin, offering comparable high-intensity LDL-C lowering (≥50% reduction) at doses of 40-80 mg daily. 1, 2

Alternative Statin Options by Intensity

High-Intensity Alternatives (≥50% LDL-C reduction)

• Atorvastatin 40-80 mg daily: The only other high-intensity statin option 3, 1
• Provides equivalent cardiovascular risk reduction to rosuvastatin in clinical trials
• Well-established safety profile with decades of outcome data

Moderate-Intensity Options (30-49% LDL-C reduction)

If high-intensity statins are not tolerated:

• Atorvastatin 10-20 mg 1
• Simvastatin 20-40 mg (avoid 80 mg due to myopathy risk) 1
• Pravastatin 40-80 mg 1
• Pitavastatin 1-4 mg 2, 4

Pitavastatin deserves special mention for patients with diabetes or metabolic syndrome, as it may reduce new-onset diabetes risk compared to other statins 4

Non-Statin Alternatives

For Statin Intolerance (Complete)

When patients cannot tolerate any statin at any dose:

1. Ezetimibe monotherapy (first-line): 10 mg daily reduces LDL-C by 20-25% 3

2. Bempedoic acid + ezetimibe combination: Reduces LDL-C by ~35-40% 3, 4

   • Particularly useful as bempedoic acid is liver-selective and causes minimal muscle symptoms
   • CLEAR Outcomes trial demonstrated cardiovascular benefit in statin-intolerant patients 5, 6

3. PCSK9 inhibitors (evolocumab or alirocumab): Reduce LDL-C by ~60% 3

   • Subcutaneous injection every 2-4 weeks
   • Proven cardiovascular benefit in FOURIER and ODYSSEY OUTCOMES trials
   • For statin-intolerant patients, evolocumab + ezetimibe provides the greatest LDL-C reduction (approximately 49% vs ezetimibe alone) 5

4. Inclisiran: PCSK9 siRNA therapy, twice-yearly dosing after loading 4, 7

For Partial Statin Intolerance

Use the maximally tolerated statin dose combined with ezetimibe upfront, rather than slowly titrating statin doses 4. This approach:

• Achieves target LDL-C faster
• Reduces visit-to-visit LDL-C variability (which independently increases cardiovascular events)
• Minimizes muscle symptoms by avoiding high statin doses

Rechallenge Strategy for Suspected Intolerance

Before declaring complete statin intolerance, attempt at least 2-3 different statins, including at least one at the lowest approved dose 8, 9:

1. Try pravastatin or fluvastatin first (most hydrophilic, least muscle symptoms) 10
2. Consider intermittent dosing: Rosuvastatin 5-10 mg weekly or atorvastatin 2-3 times weekly can still provide meaningful LDL-C reduction (17-32%) with better tolerability 9
3. 92% of patients with suspected statin intolerance can tolerate rechallenge 9

Target-Based Treatment Algorithm

Very High-Risk Patients (LDL-C goal <55 mg/dL or <1.4 mmol/L)

Examples: Recent ACS, established ASCVD, recurrent events

1. Start atorvastatin 40-80 mg 3
2. Add ezetimibe at 4-6 weeks if LDL-C ≥55 mg/dL 3, 4
3. Add PCSK9 inhibitor at 4-6 weeks if still ≥55 mg/dL on statin + ezetimibe 3
4. Consider bempedoic acid if PCSK9 inhibitors unavailable 3

Extreme Risk Patients (recurrent event within 2 years on maximal therapy)

• Consider LDL-C goal <40 mg/dL (<1.0 mmol/L) 3
• May require triple or quadruple therapy (statin + ezetimibe + PCSK9 inhibitor + bempedoic acid) 4

Special Populations

Patients with Diabetes/Metabolic Syndrome

Consider pitavastatin + ezetimibe combination upfront 4:

• Pitavastatin reduces new-onset diabetes risk
• Alternative: Lower-dose high-intensity statin (rosuvastatin 20 mg or atorvastatin 40 mg) + ezetimibe
• Add bempedoic acid if needed (may improve glycemic control) 4

Asian Populations

May require lower statin doses due to greater pharmacokinetic response 1

Critical Pitfalls to Avoid

1. Do NOT use simvastatin 80 mg - FDA warning for increased myopathy/rhabdomyolysis risk 1, 2

2. Do NOT delay combination therapy - Waiting months to add ezetimibe increases LDL-C variability and cardiovascular risk 4

3. Do NOT assume all muscle symptoms are statin-related - 92% can tolerate rechallenge; many symptoms have other causes 9

4. Do NOT use fibrates or niacin routinely with statins - No proven cardiovascular benefit as add-on therapy, increased myopathy risk 1

5. Monitor INR closely when switching statins in warfarin users - All statins can affect INR 11